Market revenue in 2023 | USD 53.4 million |
Market revenue in 2030 | USD 108.8 million |
Growth rate | 10.7% (CAGR from 2023 to 2030) |
Largest segment | Surgery |
Fastest growing segment | Intralesional injections |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Radiotherapy (RT), Intralesional injections, Intravenous Medications, Chemical peeling treatment, Surgery, Topical chemotherapy, Oral Medications |
Key market players worldwide | Bausch Health Companies Inc, Almirall SA, Genentech, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Dr Reddy's Laboratories Ltd ADR, Taro Pharmaceuticals, Accord Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to basal cell carcinoma treatment market will help companies and investors design strategic landscapes.
Surgery was the largest segment with a revenue share of 35.96% in 2023. Horizon Databook has segmented the Japan basal cell carcinoma treatment market based on radiotherapy (rt), intralesional injections, intravenous medications, chemical peeling treatment, surgery, topical chemotherapy, oral medications covering the revenue growth of each sub-segment from 2018 to 2030.
Japan is one of the most advanced countries in this region, and the country’s basal cell carcinoma treatment market in the country is expected to grow rapidly, owing to high government spending to curb cancer prevalence.
The increase in cancer prevalence can be attributed to rapid growth in the geriatric population. Japan has a median age of 44 years, one of the highest in the world. In contrast to other Asia Pacific countries.
Japan offers country-wide cancer screening programs to combat its growing prevalence. This program offers cancer screening to over 94% of the population. However, stringent policies by regulatory agencies delay the introduction of newer technologies in the market.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan basal cell carcinoma treatment market , including forecasts for subscribers. This country databook contains high-level insights into Japan basal cell carcinoma treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account